Clinical Study of Super Transplantation in the Treatment of Severe β-thalassemia
Overview
- Phase
- Not Applicable
- Intervention
- super-transplantation in 3 severe β -thalassemia pediatric patients.
- Conditions
- Thalassemia Majors (Beta-Thalassemia Major)
- Sponsor
- Guangzhou Women and Children's Medical Center
- Enrollment
- 3
- Locations
- 1
- Primary Endpoint
- chimeric status
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
This is a single-arm, open label, phase 1 study in subjects with beta-thalassemia. This study will evaluate the safety and efficacy of preconditioning-free super-transplantation on beta-thalassemia pediatric patients.
Detailed Description
Patient screening: 1. Two months before transplantation, pediatric patients are evaluated by our center, and the patients meeting the inclusion criteria will be screened into the group. 2. Investigators and doctors will give detailed information about the benefits and risks of participating in the study, and the informed consents are further signed. Transplant conduction: 1. Donor mobilization: HLA-fully matched or haplo-identical donors are mobilized subcutaneously for five days with human granulocyte colony-stimulating factor (G-CSF) and the peripheral blood mononuclear cells (PBMCs) that contain a certain numbers of CD34+ stem cells and CD3+ lymphocytes will be extracted by blood cell separators. 2. Transplant regimen: Hydroxycarbamide will be used to reduce the total white blood cells before transplant. However, no traditional transplantation conditioning will be performed, including but not limited to busulfan, fludarabine, Cyclophosphamide, ATG, and irradiation. Splenectomy should be performed if the longitudinal diameter of the spleen exceeds the normal value by 4 cm. 3. Cell infusion: Pediatric patients will be infused with the PBMCs intravenously at day 0. 4. GVHD prophylaxis: The dosage of immunosuppressants is half of the conventional post-transplantation level, but adjustments to the dosage may be necessary based on specific circumstances. 5. Infection management: Antibacterial, antifungal medications, and anti-Pneumocystis medications need to be administered during the period of granulocytopenia. The preemptive treatment for cytomegalovirus will be performed when the virus serological test is positive.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of severe β -thalassemia
- •Age between 7-10 years old, male and female; Weight \< 40kg
- •The patient has or does not have an HLA-compatible or semi-compatible donor, but unconditional transplantation or refusal of blood stem cell transplantation; Patients with thalassemia gene therapy without conditions or refusal;
- •There are fully compatible or incompatible HLA donors, and the physical examination meets the donor conditions;
- •The patient and family members agree to receive hypertransplant therapy and sign a written informed consent prior to the transplant trial.
Exclusion Criteria
- •Mental patients;
- •Participants in other drug clinical trials within the past 1 month;
- •There are no suitable HLA-incompatible donors.
- •Other researchers decide that it is not suitable to participate in this researcher.
Arms & Interventions
Severe β -thalassemia
Children with β-thalassemia major received super transplantation, and chimerism tests were performed at 3 months, 6 months, 9 months, and 1 year after transplantation to evaluate the safety and effectiveness.
Intervention: super-transplantation in 3 severe β -thalassemia pediatric patients.
Outcomes
Primary Outcomes
chimeric status
Time Frame: 1 year after transplantation.
Detecting the chimerism in recipients' peripheral blood and bone marrow.Chimerism is generally measured in percentages(%)